Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet Psychiatry

Volumn 4, Issue 8, 2017, Pages 595-604

  Anderson, Karen E ^a   Stamler, David ^b   Davis, Mat D ^c   Factor, Stewart A ^d   Hauser, Robert A ^e   Isojärvi, Jouko ^c   Jarskog, L Fredrik ^f   Jimenez Shahed, Joohi ^g   Kumar, Rajeev ^h   McEvoy, Joseph P ⁱ   Ochudlo, Stanislaw ^j   Ondo, William G ^k   Fernandez, Hubert H ^l  

^a GEORGETOWN UNIVERSITY   (United States)

^b Teva Pharmaceutical Industries   (United States)

^c Teva Pharmaceutical Industries   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h Rocky Mountain Movement Disorders Center   (United States)

ⁱ MEDICAL COLLEGE OF GEORGIA   (United States)

^j Specialist Medical Practice   (Poland)

^k HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEUTETRABENAZINE; DOPAMINE RECEPTOR BLOCKING AGENT; TETRABENAZINE;

ADULT; AGED; AKATHISIA; ANXIETY; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MUSCLE SPASM; NAUSEA; PARKINSONISM; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEDATION; SOMNOLENCE; SUICIDAL IDEATION; TARDIVE DYSKINESIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; ABNORMAL INVOLUNTARY MOVEMENT SCALE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; EUROPE; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; UNITED STATES;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGED; DOUBLE-BLIND METHOD; DYSKINESIAS; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; TARDIVE DYSKINESIA; TETRABENAZINE; TREATMENT OUTCOME; UNITED STATES;

EID: 85021358072     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30236-5     Document Type: Article

References (29)

1. Aquino, CCH, Lang, AE, Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord 20:suppl 1 (2014), S113–S117.
2. Tarsy, D, Lungu, C, Baldessarini, RJ, Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. William, JW, Eduardo, T, (eds.) Handbook of clinical neurology, 2011, Elsevier, Amsterdam, 601–616.
3. Woods, SW, Morgenstern, H, Saksa, JR, et al. Incidence of tardive dyskinesia with atypical and conventional antipsychotic medications: prospective cohort study. J Clin Psychiatry 71 (2010), 463–474.
4. Correll, CU, Leucht, S, Kane, JM, Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies. Am J Psychiatry 161 (2004), 414–425.
5. Carbon, M, Hsieh, CH, Kane, JM, Correll, CU, Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry 78 (2017), e264–e278.
6. Jankelowitz, SK, Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat 9 (2013), 1371–1380.
7. Waln, O, Jankovic, J, An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (NY), 3, 2013 tre-03-161-4138-1.
8. Gerlach, J, Hansen, L, Clozapine and D1/D2 antagonism in extrapyramidal functions. Br J Psychiatry 17:suppl (1992), 34–37.
9. Trugman, JM, Tardive dyskinesia: diagnosis, pathogenesis, and management. Neurologist 4 (1998), 180–187.
10. Caroff, SN, Hurford, I, Lybrand, J, Campbell, EC, Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 29 (2011), 127–148.
11. Zutshi, D, Cloud, LJ, Factor, SA, Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (NY), 4, 2014, 266.
12. Chang, FC, Fung, VS, Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders. Pharmgenomics Pers Med 7 (2014), 317–328.
13. Chou, KL, Friedman, JH, Tardive syndromes in the elderly. Clin Geriatr Med 22 (2006), 915–933.
14. Lerner, PP, Miodownik, C, Lerner, V, Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci 69 (2015), 321–334.
15. Bhidayasiri, R, Boonyawairoj, S, Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J 87 (2011), 132–141.
16. Erickson, JD, Schafer, MK, Bonner, TI, Eiden, LE, Weihe, E, Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 93 (1996), 5166–5171.
17. Fasano, A, Bentivoglio, AR, Tetrabenazine. Exp Opin Pharmacother 10 (2009), 2883–2896.
18. Lundbeck. Xenazine prescribing information. https://www.lundbeck.com/upload/us/files/pdf/Products/Xenazine_PI_US_EN.pdf, 2015 (accessed May 10, 2017).
19. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66 (2006), 366–372.
20. Kenney, C, Hunter, C, Jankovic, J, Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 22 (2007), 193–197.
21. Shao, L, Hewitt, MC, The kinetic isotope effect in the search for deuterated drugs. Drug News Perspect 23 (2010), 398–404.
22. Stamler, D, Bradbury, M, Brown, F, The pharmacokinetics and safety of deuterated-tetrabenazine. Neurology, 80(suppl), 2013 P07.210.
23. Huntington Study Group, Frank, S, Testa, CM, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA 316 (2016), 40–50.
24. Jankovic, J, Jimenez-Shahed, J, Budman, C, et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (NY), 6, 2016, 422.
25. Hauser, RA, Factor, SA, Marder, SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 174 (2017), 476–484.
26. Fernandez, HH, Factor, SA, Hauser, RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology 88 (2017), 2003–2010.
27. Flake, ZA, Scalley, RD, Bailey, AG, Practical selection of antiemetics. Am Fam Physician 69 (2004), 1169–1174.
28. Chang, FCF, Fung, VSC, Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders. Pharmgenomics Pers Med 7 (2014), 317–328.
29. Epping, EA, Kim, JI, Craufurd, D, et al. Longitudinal psychiatric symptoms in prodromal Huntington's disease: a decade of data. Am J Psychiatry 173 (2016), 184–192.